MN8 Energy Signs Supply Agreement with Eos Energy to Deploy Up to 750 MWh of American-Made Long Duration Energy Storage Across Renewable Projects

(NASDAQ:EOSE), PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS), today announced a supply agreement for as much as 750 MWh with MN8 Energy, one of the […]

aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit — Hagens Berman

A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims. Blog:www.hbsslaw.com/blog

MN8 Energy Signs Supply Agreement with Eos Energy to Deploy Up to 750 MWh of American-Made Long Duration Energy Storage Across Renewable Projects

MN8 Energy Signs Supply Agreement with Eos Energy to Deploy Up to 750 MWh of American-Made Long Duration Energy Storage Across Renewable Projects Agreement underscores growing demand for U.S.-made energy storage that strengthens reliability and delivers long-duration flexibility to meet the needs of high-demand sectors GlobeNewswire October 21, 2025 PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE)

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman

MLTX Investors with Losses Encouraged to Contact Hagens Berman A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa

Dynamic and Engaging: Porsche introduces the first electric Macan GTS

Atlanta, GA., Oct. 21, 2025 (GLOBE NEWSWIRE) — Porsche is expanding the Macan Electric model range with a particularly dynamic variant: The 2026 Macan GTS. With up to 420 kW (563 hp) of Overboost power, limited slip rear differential and a sport-tuned air suspension with lower ride height, the Macan GTS aims to offer the

Dynamic and Engaging: Porsche introduces the first electric Macan GTS

Dynamic and Engaging: Porsche introduces the first electric Macan GTS Fifth model in the range GlobeNewswire October 21, 2025 Atlanta, GA., Oct. 21, 2025 (GLOBE NEWSWIRE) — Porsche is expanding the Macan Electric model range with a particularly dynamic variant: The 2026 Macan GTS. With up to 420 kW (563 hp) of Overboost power, limited

HII Increases Quarterly Dividend to $1.38 per Share

(NYSE:HII), NEWPORT NEWS, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Board of Directors has declared a quarterly cash dividend of $1.38 per share, a $0.03 increase over the $1.35 per share dividend paid in each of the prior four quarters. The $1.38 per share dividend will be payable

Defiance Launches IRE: The First 2X Long ETF for IREN Limited

(NASDAQ:IREN),(NasdaqGM:IRE), MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) — Defiance ETFs is proud to announce the launch of the Defiance Daily Target 2X Long IREN ETF (Ticker: IRE), expanding its suite of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative, high-growth companies. The newest addition, IRE, is designed for traders who seek

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

(NASDAQ:CERO), Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, today announced that

Eos Energy Executes Next Phase of Growth Strategy with U.S. Manufacturing Expansion and New Software Hub Under Project AMAZE

(NASDAQ:EOSE), $24 million state-led economic development package underscores the shared commitment between Eos and Pennsylvania to advance U.S. manufacturing and job creation Expansion reinforces the Company's progress and transformation as Pennsylvania becomes a national hub for energy, technology, and manufacturing innovation PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”

Scroll to Top